Literature DB >> 8321628

Effects of dichloroacetate on exercise performance in healthy volunteers.

B Ludvik1, G Mayer, S Stifter, D Putz, U Barnas, H Graf.   

Abstract

Dichloroacetate (DCA), a stimulator of the pyruvate dehydrogenase complex, decreases lactate levels and peripheral resistance and increases cardiac output. This study was performed to examine the effects of DCA on exercise performance in humans. Eight healthy male volunteers (age 20-28 years) were tested by bicycle spiro-ergometry using a microprocessor-controlled gas analysis system after infusion of DCA (50 mg/kg body weight) or saline. Prior infusion of DCA significantly reduced the increase of lactate levels during exercise when compared with infusion of saline (1.40 +/- 0.21 vs 2.10 +/- 0.09 mmol.l-1 at 50% of the expected maximal working capacity, P < 0.05; 8.53 +/- 0.45 vs 9.92 +/- 0.59 mmol.l-1 at maximal working capacity, P < 0.05). Oxygen uptake increased significantly after DCA when compared with saline from 7.5 +/- 0.4 vs 7.4 +/- 0.5 to 27.2 +/- 1.5 vs 23.7 +/- 1.7 (P < 0.05) at anaerobic threshold and to 35.6 +/- 1.7 vs 30.5 +/- 1.0 ml.kg-1 min-1 (P < 0.05) at maximal exercise capacity. Following DCA infusion the workload at which the anaerobic threshold was reached was significantly higher (160 +/- 7 vs 120 +/- 5 W, P < 0.05) and the maximal working capacity was significantly increased (230 +/- 9 vs 209 +/- 8 W, P < 0.05). In summary, DCA reduced the increase of lactate levels during exercise and increased oxygen uptake at the anaerobic threshold and at maximal working capacity, which was significantly increased. These results warrant further studies on a potential therapeutic application of DCA in patients with reduced exercise capacity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321628     DOI: 10.1007/bf00374403

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  17 in total

1.  Regulation of glycolysis and pyruvate oxidation in cardiac muscle.

Authors:  P J Randle
Journal:  Circ Res       Date:  1976-05       Impact factor: 17.367

2.  Dichloroacetate in the treatment of lactic acidosis.

Authors:  P W Stacpoole; A C Lorenz; R G Thomas; E M Harman
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

3.  Anaerobic threshold and respiratory gas exchange during exercise.

Authors:  K Wasserman; B J Whipp; S N Koyl; W L Beaver
Journal:  J Appl Physiol       Date:  1973-08       Impact factor: 3.531

4.  Effect of dichloroacetate sodium on the lactacidemia of experimental endotoxin shock.

Authors:  G F Merrill; M Rosolowsky
Journal:  Circ Shock       Date:  1980

Review 5.  The pharmacology of dichloroacetate.

Authors:  P W Stacpoole
Journal:  Metabolism       Date:  1989-11       Impact factor: 8.694

6.  Effects of dichloroacetate and bicarbonate on haemodynamic parameters in healthy volunteers.

Authors:  B Ludvik; G Peer; A Berzlanovich; S Stifter; H Graf
Journal:  Clin Sci (Lond)       Date:  1991-01       Impact factor: 6.124

7.  Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia.

Authors:  P W Stacpoole; G W Moore; D M Kornhauser
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

8.  Treatment of lactic acidosis with dichloroacetate.

Authors:  P W Stacpoole; E M Harman; S H Curry; T G Baumgartner; R I Misbin
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

9.  Metabolic effects of dichloroacetate in diabetic dogs.

Authors:  R Park; P R Radosevich; W J Leach; P Seto; A I Arieff
Journal:  Am J Physiol       Date:  1983-07

10.  Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids.

Authors:  S Whitehouse; R H Cooper; P J Randle
Journal:  Biochem J       Date:  1974-09       Impact factor: 3.857

View more
  6 in total

Review 1.  Enhancing physical performance in chronic obstructive pulmonary disease.

Authors:  M C Steiner; M D Morgan
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

2.  Tricarboxylic acid cycle intermediates accumulate at the onset of intense exercise in man but are not essential for the increase in muscle oxygen uptake.

Authors:  Jens Bangsbo; Martin J Gibala; Krista R Howarth; Peter Krustrup
Journal:  Pflugers Arch       Date:  2006-05-24       Impact factor: 3.657

3.  Carnitine Acetyltransferase Mitigates Metabolic Inertia and Muscle Fatigue during Exercise.

Authors:  Sarah E Seiler; Timothy R Koves; Jessica R Gooding; Kari E Wong; Robert D Stevens; Olga R Ilkayeva; April H Wittmann; Karen L DeBalsi; Michael N Davies; Lucas Lindeboom; Patrick Schrauwen; Vera B Schrauwen-Hinderling; Deborah M Muoio
Journal:  Cell Metab       Date:  2015-07-07       Impact factor: 27.287

Review 4.  An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

5.  Substrate availability limits human skeletal muscle oxidative ATP regeneration at the onset of ischemic exercise.

Authors:  J A Timmons; T Gustafsson; C J Sundberg; E Jansson; E Hultman; L Kaijser; J Chwalbinska-Moneta; D Constantin-Teodosiu; I A Macdonald; P L Greenhaff
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

6.  Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.

Authors:  Que Liu; Christen Anderson; Anatoly Broyde; Clara Polizzi; Rayne Fernandez; Alain Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-11-16       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.